A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Hyperkalemia

In brief

This phase 2, single-blind, placebo-controlled study will evaluate the onset-of-action, safety, and efficacy of RDX227675 for the treatment of hyperkalemia. Subjects who qualify are randomized into one of four treatment groups: Group 1 (Placebo qd), Group 2 (RDX227675 10 g qd), Group 3 (RDX227675 20 g qd), Group 4 (RDX227675 30 g qd).

Key facts

Study ID

NCT03018067

Run by

Ardelyx

People needed

60

Starts

2017-01-01

Expected to finish

2017-05-01

Last updated by the study team

2019-12-26

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 to 85 years old, inclusive
• Two consecutive i-STAT K values ≥ 5.5 to < 6.5 mmol/L, measured a minimum of 60-minutes apart within 1 day of first RDX227675 dose on Day 1 (prior to randomization)
• i-STAT K value ≥ 5.5 to < 6.5 mmol/L on Day 1 (prior to randomization)
• Ability to have repeated blood draws or effective venous catheterization
• Females of child bearing potential must have negative urine pregnancy test on Day 1 (prior to randomization)
• Females but be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods
• Males must agree to use an appropriate method of contraception or have documented surgical sterilization

You may not qualify if…

• Pseudohyperkalemia signs and symptoms
• Treatment with K lowering drugs, within 7 days prior to randomization
• Uncontrolled Type 2 diabetes, as defined as most recent historical HbA1c > 10%, or hospitalization to treat hyper- or hypo-glycemia in the past 3 months
• Diabetic ketoacidosis
• Known hypersensitivity to polystyrene sulfonate
• Significant cardiovascular or cerebrovascular events in the past 2 months
• Severe heart failure, defined as NYHA (New York Heart Association) class IV or hospitalization to treat heart failure in previous 3 months
• History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders, or major gastrointestinal surgery
• Major psychiatric disorder (DSM-III-R or DSM-IV) including major depression or other psychoses that has required hospitalization in the last 3 years. History of attempted suicide or uncontrolled bipolar disorder.
• Use of an investigational product within 30 days prior to Screening

Where it is running

• Capital Nephrology Associates, PA — Cary, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.